Department of Neurology, Sørlandet Hospital, Kristiansand, Norway.
Acta Neurol Scand. 2011 Jun;123(6):396-9. doi: 10.1111/j.1600-0404.2010.01411.x.
To examine multiple sclerosis (MS) prevalence, rate of immunomodulatory treatment and frequency of Borrelia burgordorferi (Bb) antibodies in Vest-Agder, Norway.
Patients in the period 1996-2006 who met the Poser criteria for definitive or probable MS were included. Clinical and demographical data, and presence of Bb antibodies were registered.
A total of 295 patients were identified. The crude prevalence was 180 per 100,000 population (95% CI=160.9-218.0), age-adjusted prevalence was 186 per 100,000 population (95% CI=166.3-225.3). The age-adjusted incidence rates were 7.5 and 8.0 for 1996-2000 and 2001-2006, respectively. Thirty-eight per cent were treated with immunomodulatory agents when compared to 28% in the rest of the country. Bb serum antibodies were detected in 7% of patients with MS.
Vest-Agder county has the highest prevalence of MS reported in Norway, and a high treatment rate. Bb antibodies were not more prevalent than in healthy individuals.
调查挪威韦斯特兰郡多发性硬化症(MS)的流行率、免疫调节治疗率和伯氏疏螺旋体(Bb)抗体频率。
纳入 1996 年至 2006 年间符合波塞标准的确诊或可能 MS 患者。记录临床和人口统计学数据以及 Bb 抗体的存在情况。
共确定了 295 名患者。粗患病率为 180/100,000 人(95%CI=160.9-218.0),年龄调整后的患病率为 186/100,000 人(95%CI=166.3-225.3)。1996-2000 年和 2001-2006 年的年龄调整发病率分别为 7.5 和 8.0。与全国其他地区的 28%相比,38%的患者接受了免疫调节剂治疗。MS 患者中有 7%检测到 Bb 血清抗体。
韦斯特兰郡的 MS 患病率居挪威之首,且治疗率较高。Bb 抗体的流行率并不高于健康人群。